Breaking News

PAREXEL Expands Genomic Research Services

February 17, 2016

Offers strategic and operational genomic research services aimed at accelerating drug development

PAREXEL International has expanded its services and capabilities for genomic-based drug development. The PAREXEL Genomic Medicine team now offers a variety of strategic and operational genomic research services aimed at accelerating drug development and to support regulatory and payer approval processes.
 
Increasingly, biopharma companies are applying genomics to drug discovery and development in an effort to better understand the genetic basis of disease, and regulators and payers are increasingly seeking genomic information to make more informed decisions.
 
“Recently, the terms ‘precision medicine’ and ‘personalized medicine’ have become household terms, and genomic research is the key to developing targeted therapies. By applying innovative and state-of-the-art methodologies, we work with our clients to understand how genes impact an individual’s response to treatment – and why people who receive the same treatment may respond differently,” said Sy Pretorius, M.D., chief scientific officer, PAREXEL. “PAREXEL’s Genomic Medicine team leverages genomic information across more than 10 therapeutic areas to help biopharmaceutical companies discover, develop, and secure regulatory and payer approval for their new medicines.”
 
PAREXEL’s Genomic Medicine team is comprised of more than 15 scientists with experience in genomics, drug discovery, and drug development. The team joined PAREXEL from GlaxoSmithKline’s Genetics and Computational Biology departments.
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems